文献速递垂体与肾上腺疾病性腺与生殖内分泌甲状腺疾病

儿童癌症幸存者下丘脑-垂体放疗后缺陷与TNS2罕见变异相关

Hypothalamic-pituitary deficiency after radiation in childhood cancer survivors is associated with rare variants in TNS2.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

该研究基于St. Jude终身队列中809例接受下丘脑-垂体放疗的5年幸存者(中位随访31.9年),评估罕见变异与垂体激素缺乏的关联。携带TNS2罕见变异的幸存者发生下丘脑-垂体缺陷的速率显著更高(速率比2.72,95%CI 1.81-4.09,P=1.5×10⁻⁵),且在儿童癌症幸存者研究中重复验证;全基因组关联分析未发现显著变异。

要点

  • TNS2罕见变异携带者下丘脑-垂体缺陷发生率显著升高,速率比2.72。
  • LH/FSH、TSH、ACTH缺乏单独分析也显示与TNS2罕见变异相关。
  • 全基因组常见变异分析未发现与放疗后垂体缺陷显著关联的位点。

核心结论

  • TNS2可能参与放疗诱导的下丘脑-垂体缺陷发生。
  • 筛查TNS2变异经进一步验证后或有助于识别需要加强监测和干预的个体。

研究设计与样本

  • 基于St. Jude终身队列,纳入809例接受下丘脑-垂体放疗的5年幸存者,中位随访31.9年。
  • 对801例幸存者全外显子测序罕见变异(MAF<0.01且功能预测致病)与垂体缺陷发生率进行关联分析,采用精确泊松检验。
  • 对606例欧洲 ancestry 且有全基因组序列数据的幸存者进行GWAS(MAF≥0.01),并在儿童癌症幸存者研究1328例中重复验证。

主要发现

  • TNS2罕见变异携带者下丘脑-垂体缺陷总发生率显著高于非携带者(速率比2.72,95%CI 1.81-4.09,P=1.5×10⁻⁵),并在儿童癌症幸存者研究中重复验证。
  • LH/FSH缺乏(速率比3.31,95%CI 1.28-7.99)、TSH缺乏(5.29,95%CI 2.42-11.34)、ACTH缺乏(3.97,95%CI 1.05-12.31)单独分析亦与TNS2罕见变异相关。
  • GWAS未发现统计学显著的相关变异。

临床怎么用

  • 对接受下丘脑-垂体放疗的儿童癌症幸存者,可考虑评估TNS2罕见变异以辅助风险分层(需进一步验证)。
  • 携带TNS2罕见变异者可能需更密切监测生长激素、性腺、甲状腺和肾上腺轴功能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Radiation to the hypothalamic-pituitary (HP) region (HP-RT) is a strong risk factor for HP deficiency among childhood cancer survivors (survivors). However, there is inter-individual variability in developing HP deficiency after similar HP-RT dose exposures. OBJECTIVES: To assess the genetic contribution to developing deficiencies of GH (GHD), LH/FSH (LH/FSHD), thyroid-stimulating hormone deficiency (thyroid-stimulating hormone deficiency [TSHD]), and ACTH (adrenocorticotropic hormone deficiency [ACTHD]) among survivors exposed to HP-RT. METHODS: Eligible participants included 5-year survivors exposed to HP-RT (n = 809; median follow-up 31.9 years) from the St. Jude Lifetime Cohort. We assessed the association between rare variants from whole-exome sequencing data (minor allele frequency [MAF] < 0.01, predicted to be pathogenic by functional prediction tools) and HP deficiency rate (total counts/person-year) among 801 survivors by the exact Poisson test. Genome-wide association analysis (GWAS) was conducted among 606 survivors of European ancestry with available whole-genome sequence data, targeting variants with MAF ≥ 0.01. The replication population was 1328 survivors from the Childhood Cancer Survivor Study (CCSS). RESULTS: Carriers of rare variants in TNS2, a ubiquitously expressed protein-coding gene including in brain, had significantly higher rates of HP deficiencies (rate ratio 2.72 [95% CI 1.81-4.09], P = 1.5 × 10-5) compared to non-carriers, which was replicated in the CCSS. This was also observed in individual HP deficiencies: LH/FSHD (3.31 [1.28-7.99]), TSHD (5.29 [2.42-11.34]), and ACTHD (3.97 [1.05-12.31]). There were no statistically significant variants in GWAS. CONCLUSION: TNS2 may contribute to radiation-induced HP deficiencies. With further validation, screening for TNS2 variants has potential to help identify individuals who would benefit from surveillance and intervention following HP-RT.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Yoshida T, Wang F, Moon W, et al. Hypothalamic-pituitary deficiency after radiation in childhood cancer survivors is associated with rare variants in TNS2. J Clin Endocrinol Metab. 2026. PMID: 41739851. doi:10.1210/clinem/dgag080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。